Inceptionr LLC Sells 3,134 Shares of Tenet Healthcare Corporation $THC

Inceptionr LLC decreased its holdings in Tenet Healthcare Corporation (NYSE:THC) by 49.4% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,208 shares of the company’s stock after selling 3,134 shares during the quarter. Inceptionr LLC’s holdings in Tenet Healthcare were worth $651,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. William B. Walkup & Associates Inc. bought a new stake in shares of Tenet Healthcare during the 3rd quarter valued at $32,000. Westside Investment Management Inc. raised its stake in Tenet Healthcare by 100.0% in the third quarter. Westside Investment Management Inc. now owns 192 shares of the company’s stock valued at $39,000 after buying an additional 96 shares during the period. Trust Co. of Vermont acquired a new position in shares of Tenet Healthcare in the third quarter valued at approximately $41,000. Canada Pension Plan Investment Board bought a new position in Tenet Healthcare during the 2nd quarter worth $35,000. Finally, Geneos Wealth Management Inc. increased its position in Tenet Healthcare by 50.9% during the second quarter. Geneos Wealth Management Inc. now owns 264 shares of the company’s stock worth $46,000 after acquiring an additional 89 shares during the period. 95.44% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Nadja West sold 2,178 shares of the firm’s stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $197.47, for a total value of $430,089.66. Following the transaction, the director owned 28,480 shares of the company’s stock, valued at $5,623,945.60. This trade represents a 7.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Thomas W. Arnst sold 24,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $234.04, for a total value of $5,616,960.00. Following the transaction, the executive vice president owned 8,012 shares in the company, valued at $1,875,128.48. The trade was a 74.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 42,195 shares of company stock valued at $9,823,406 in the last three months. Corporate insiders own 0.81% of the company’s stock.

Tenet Healthcare Trading Down 1.4%

Shares of Tenet Healthcare stock opened at $237.30 on Wednesday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.68 and a current ratio of 1.76. The company has a fifty day moving average of $211.66 and a 200 day moving average of $203.29. The company has a market capitalization of $20.64 billion, a P/E ratio of 15.32, a P/E/G ratio of 1.19 and a beta of 1.39. Tenet Healthcare Corporation has a fifty-two week low of $109.82 and a fifty-two week high of $247.21.

Tenet Healthcare (NYSE:THC) last released its earnings results on Wednesday, February 11th. The company reported $4.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.08 by $0.62. Tenet Healthcare had a return on equity of 26.33% and a net margin of 6.60%.The firm had revenue of $5.53 billion during the quarter, compared to analysts’ expectations of $5.47 billion. During the same quarter last year, the business posted $3.44 earnings per share. The firm’s revenue was up 8.9% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 16.190-18.470 EPS. On average, sell-side analysts anticipate that Tenet Healthcare Corporation will post 12.24 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on THC shares. Cantor Fitzgerald restated an “overweight” rating on shares of Tenet Healthcare in a research report on Wednesday, March 4th. JPMorgan Chase & Co. upped their price target on shares of Tenet Healthcare from $200.00 to $230.00 and gave the company an “overweight” rating in a research note on Thursday, November 13th. Weiss Ratings upgraded shares of Tenet Healthcare from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Monday, December 29th. Guggenheim raised their price objective on Tenet Healthcare from $257.00 to $271.00 and gave the company a “buy” rating in a research report on Friday, February 13th. Finally, Truist Financial boosted their price objective on shares of Tenet Healthcare from $240.00 to $270.00 and gave the company a “buy” rating in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $247.67.

Tenet Healthcare Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.